Molecular Partners Ag (MOLN) Return on Capital Employed (2021 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Return on Capital Employed of 215357.42% for Q1 2026, down 21535732.0% year-over-year from N/an in Q1 2025, and down 25.82% quarter-over-quarter from 171159.25% in Q4 2025.
Molecular Partners Ag (MOLN) Return on Capital Employed (2021 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Return on Capital Employed for 6 consecutive years, with 215357.42% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 21535732.0% year-over-year to 215357.42%; the TTM figure through Mar 2026 stood at 215357.42% (down 21535732.0% YoY), while the FY2025 annual figure was 80.39%, down 4360.0% from the prior year.
- Return on Capital Employed retreated to 215357.42% in Q1 2026 per MOLN's latest filing, from 171159.25% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 0.22% in Q1 2023 and bottomed at 215357.42% in Q1 2026.
- Historically, Return on Capital Employed has averaged 31546.21% across 5 years, with a median of 0.08% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 31 bps — and 2026, when it sank 21535732 bps.
- Molecular Partners Ag's Return on Capital Employed stood at 0.2% in 2022, then sank by 134 bps to 0.07% in 2023, then plunged by 32 bps to 0.09% in 2024, then sank by 190894707 bps to 171159.25% in 2025, then fell by 26 bps to 215357.42% in 2026.
- Business Quant data shows MOLN's Return on Capital Employed at 215357.42% in Q1 2026, 171159.25% in Q4 2025, and 149768.92% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | 7.88% |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - | 54.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -215,357.42% |
| Dec 31, 2025 | -171,159.25% |
| Sep 30, 2025 | -149,768.92% |
| Jun 30, 2025 | -0.11% |
| Mar 31, 2025 | -0.10% |
| Dec 31, 2024 | -0.09% |
| Sep 30, 2024 | -0.09% |
| Jun 30, 2024 | -0.08% |
| Mar 31, 2024 | -0.08% |
| Dec 31, 2023 | -0.07% |
| Sep 30, 2023 | 0.09% |
| Jun 30, 2023 | 0.08% |
| Mar 31, 2023 | 0.22% |
| Dec 31, 2022 | 0.20% |
| Sep 30, 2022 | 0.06% |
| Jun 30, 2022 | 0.05% |
| Mar 31, 2022 | -0.06% |
| Dec 31, 2021 | -0.11% |